HIGHLIGHTS
- who: Shuo Yang and collaborators from the School of Pharmacy, Southwest Medical University, Luzhou, China have published the Article: Targeting TLR2/Rac1/cdc42/JNK Pathway to Reveal That Ruxolitinib Promotes Thrombocytopoiesis, in the Journal: (JOURNAL) of 18/Oct/2022
- what: The authors demonstrated that ruxolitinib has the ability to promote MK maturation and platelet production by in_vitro identification of activity. The study provides new pharmacological insights into ruxolitinib. The authors showed that Rac1, cdc42, and JNK are activated downstream of the targeting action of ruxolitinib with TLR2 and are involved in proplatelet formation . In this . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.